CoChat

Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D 1 or D 2 Receptor Agonists

Morissette, Marc, Grondin, Richard, Goulet, Martin, Bédard, Paul J., Di Paolo, Thérèse · 1999 · Journal of Neurochemistry
Cited by 101

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Studies in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐lesioned monkeys and in parkinsonian patients show elevated preproenkephalin (PPE) mRNA levels, unaltered by chronic l‐DOPA therapy, whereas preprotachykinin (PPT) mRNA levels are decreased by the lesion and corrected by l‐DOPA. The relative contributions of the dopamine D 1 and D 2 receptors for PPE mRNA regulation were investigated in the present study and compared with those for PPT mRNA. In situ hybridization was used to measure peptide mRNA levels in the striatum of MPTP cynomolgus monkeys after chronic 1‐month treatment with the D 1 agonist SKF‐82958, administered subcutaneously in pulsatile or continuous mode, compared with the long‐acting D 2 agonist cabergoline. Normal as well as untreated MPTP animals were also studied. PPE mRNA levels were elevated in the caudate nucleus and putamen of untreated MPTP monkeys compared with control animals with a more pronounced increase in the lateral as compared with the medial part of both structures. PPT mRNA levels showed a rostrocaudal gradient, with higher values in the middle of the caudate‐putamen and more so in the medial versus the lateral parts. PPT mRNA levels were decreased in the caudate and putamen of untreated MPTP monkeys compared with control animals, and this was observed in the middle and posterior parts of these brain areas. Elevated PPE and decreased PPT mRNA levels observed after MPTP exposure were corrected after treatment with cabergoline (0.25 mg/kg, every other day), a dose that had antiparkinsonian effects and did not give sustained dyskinesia. In contrast, elevated PPE mRNA levels observed in untreated MPTP monkeys were markedly increased by pulsatile administration of SKF‐82958 (1 mg/kg, three times daily) in two monkeys in which the parkinsonian symptoms were improved and dyskinesias developed, whereas it remained close to control values in a third one that did not display dyskinesias despite a sustained improvement in disability ; a shorter duration of motor benefit (wearing off) over time was observed in these three animals. By contrast, pulsatile administration of SKF‐82958 corrected the decreased PPT level observed in untreated MPTP monkeys. Continuous treatment with SKF‐82958 (equivalent daily dose) produced no clear antiparkinsonian and dyskinetic responses and did not alter the denervation‐induced elevation of PPE or decrease of PPT mRNA levels. The present data suggest an opposite contribution of the dopamine D 1 receptors (stimulatory) as compared with the dopamine D 2 receptors (inhibitory) on PPE mRNA, whereas a similar stimulatory contribution of D 1 or D 2 receptors is observed for PPT mRNA. An increase in PPE expression could be involved in the induction of dyskinesias and wearing off, whereas our data do not support this link for PPT. The antiparkinsonian response was associated with a correction of the lesion‐induced decrease of PPT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1471-4159.1999.0720682.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 101

Metadata

Authors
Morissette, M., Grondin, R., Goulet, M., Bédard, P. J., & Di Paolo, T.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
1999-02
Volume
72
Issue
2
Pages
682-692
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W1995563033
Cited by
101
References
1
FWCI
6.60
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D 1 or D 2 Receptor Agonists. https://app.cochat.ai/papers/10.1046/j.1471-4159.1999.0720682.x
The paper
Morissette, M., Grondin, R., Goulet, M., Bédard, P. J., & Di Paolo, T. (1999). Differential Regulation of Striatal Preproenkephalin and Preprotachykinin mRNA Levels in MPTP‐Lesioned Monkeys Chronically Treated with Dopamine D 1 or D 2 Receptor Agonists. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.1999.0720682.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.